arimoclomol has been researched along with ALS - Amyotrophic Lateral Sclerosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, M; Greensmith, L; Hanna, M; Harley, J; Patani, R; Spicer, C; Taylor, JP | 1 |
| Durham, HD; Fernandez, M; Gentil, BJ; Hermann, A; Kuta, R; Larochelle, N; Minotti, S; Nalbantoglu, JN; Pal, A; St Louis, K; Tibshirani, M | 1 |
| Andersen, PM; Atassi, N; Benatar, M; Cudkowicz, M; David, W; Schoenfeld, D; Wuu, J | 1 |
| McDermott, CJ | 1 |
| Greensmith, L; Kalmar, B; Lu, CH | 1 |
| Liščić, RM | 1 |
| Andres, CR; Blasco, H; Corcia, P; Gordon, PH; Patin, F | 1 |
| Barber, JR; Brown, RH; Cudkowicz, ME; Grasso, D; Schoenfeld, D; Shefner, JM; Shui, A; Simpson, E; Wieland, S; Yu, H; Zhang, H | 1 |
| Cheetham, ME; Gray, A; Greensmith, L; Kalmar, B; Margulis, B; Novoselov, S | 1 |
| Barber, J; Cudkowicz, M; Lanka, V; Wieland, S | 1 |
| Phukan, J | 1 |
| Edet-Amana, E; Greensmith, L; Kalmar, B | 1 |
| Dick, J; Greensmith, L; Kalmar, B; Lu, CH; Malaspina, A; Petzold, A | 1 |
| Burnstock, G; Dick, JR; Greensmith, L; Kalmar, B; Kieran, D; Riddoch-Contreras, J | 1 |
| Benn, SC; Brown, RH | 1 |
6 review(s) available for arimoclomol and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Clinical trials in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Edaravone; Humans; Hydroxylamines; Neuroprotective Agents; Research Design; Treatment Outcome | 2019 |
The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Topics: Amyotrophic Lateral Sclerosis; Animals; Endoplasmic Reticulum Chaperone BiP; Enzyme Induction; Heat-Shock Proteins; Heat-Shock Response; Humans; Hydroxylamines; Models, Biological; Molecular Targeted Therapy; Neuroprotective Agents | 2014 |
Molecular basis of ALS and FTD: implications for translational studies.
Topics: Amyotrophic Lateral Sclerosis; DNA-Binding Proteins; Frontotemporal Dementia; Humans; Hydroxylamines; Mutation; Riluzole | 2015 |
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Clinical Trials as Topic; Frontotemporal Dementia; Humans; Hydroxylamines; Memantine; Neuroprotective Agents; Riluzole; Superoxide Dismutase; Vitamin B 12 | 2016 |
Arimoclomol: a potential therapy under development for ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Cytoprotection; Drug Approval; Drug Evaluation, Preclinical; Heat-Shock Proteins; Humans; Hydroxylamines | 2009 |
Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Chaperonins; Drugs, Investigational; Heat-Shock Proteins; Heat-Shock Response; Humans; Hydroxylamines; Nerve Degeneration; Neurons; Neuroprotective Agents; Stress, Physiological; Up-Regulation | 2010 |
2 trial(s) available for arimoclomol and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; Neuroprotective Agents; Severity of Illness Index; Superoxide Dismutase-1; Survival Analysis; Treatment Outcome | 2018 |
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Blood-Brain Barrier; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged | 2008 |
7 other study(ies) available for arimoclomol and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Frontotemporal Dementia; Heat-Shock Response; Humans; Hydroxylamines; Mice; Mutation | 2023 |
Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Heat-Shock Proteins; Heat-Shock Response; Histone Deacetylase Inhibitors; HSP70 Heat-Shock Proteins; Hydroxylamines; Mice; Motor Neurons; Spinal Cord; Transcriptional Activation; Up-Regulation | 2020 |
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; Female; HSP70 Heat-Shock Proteins; Humans; Hydroxylamines; Male; Mice; Mice, Transgenic; Motor Neurons; Muscle, Skeletal; Spinal Cord; Statistics, Nonparametric; Superoxide Dismutase; Survival Analysis; Ubiquitin | 2008 |
Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animals; Choline O-Acetyltransferase; Disease Models, Animal; Disease Progression; GPI-Linked Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Hydroxylamines; Longitudinal Studies; Mice; Mice, Transgenic; Motor Neurons; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Neuromuscular Junction; Succinate Dehydrogenase; Superoxide Dismutase | 2012 |
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Hydroxylamines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscles; Neurofilament Proteins; Phosphorylation; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1; Treatment Outcome | 2012 |
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Heat-Shock Proteins; Humans; Hydroxylamines; Mice; Mice, Transgenic; Motor Neurons; Mutation; Superoxide Dismutase | 2004 |
Putting the heat on ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Heat-Shock Response; Hydroxylamines; Life Expectancy; Mice; Superoxide Dismutase | 2004 |